Biogen Idec Inc. (BIIB) Share Price ($):193.31 Price Change: -2.37 (-1.21%)

Expand Company Information
Volume 1,306,913 Avg Volume 1,544,799
Day's Low $191.80 Day's High $193.99
52-wk Low $124.23 52-wk High $199.54
Previous Close $195.68 Open Price $193.05
Dividend $NA Yield NA%
Market Cap 45,681,500,000 P/E (Forward) 24.78
Chart for BIIB
Exchange: NASDAQ Industry: Pharmaceuticals & Biotechnology Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes: What's This?
    Find a Broker »
    Article Time Date Source
    The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Daclizumab HYP in Multiple Sclerosis 8:14 AM Apr 4, 2013  PR
    Drug Firms Expand Powers to Recoup Pay 7:44 PM Apr 3, 2013  WSJ.com
    Vanguard Reopens Capital Opportunity Fund --- That's a Contrarian Opportunity 10:40 AM Apr 3, 2013  Barrons.com
    Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI(R) 4:30 PM Apr 2, 2013  PR
    Charting the Market 3:00 PM Apr 1, 2013  Barrons.com
    UPDATE: Biogen Prices Multiple-Sclerosis Drug Below Rivals 3:12 PM Mar 29, 2013 Dow Jones Global News Select
    Biogen Idec Prices Multiple-Sclerosis Drug 1:14 PM Mar 29, 2013 Dow Jones Global News Select
    Biogen Idec Prices Multiple-Sclerosis Drug Below Oral Competitor 12:18 PM Mar 29, 2013 Dow Jones Global News Select
    Moody's Lifts Outlook for Biogen on FDA Approval for Multiple Sclerosis Pill 3:20 PM Mar 28, 2013 Dow Jones Global News Select
    Biogen Idec Leads S&P After FDA Nod 11:38 AM Mar 28, 2013  Barrons.com
    Critical Alerts For Apache, Hess, Biogen, Beazer Homes, and Deckers Released By InvestorsObserver 9:31 AM Mar 28, 2013  PR
    2ND UPDATE: FDA Approves Biogen's Pill to Treat Multiple Sclerosis 7:01 PM Mar 27, 2013 Dow Jones Global News Select
    Correction to Stories About FDA's Approval of Biogen's MS Pill 6:45 PM Mar 27, 2013 Dow Jones Global News Select
    FDA Approves Biogen Pill for Multiple Sclerosis 5:58 PM Mar 27, 2013  WSJ.com
    UPDATE: FDA Approves Biogen's Pill to Treat Multiple Sclerosis 5:51 PM Mar 27, 2013 Dow Jones Global News Select
    Biogen Idec's TECFIDERA(TM) (Dimethyl Fumarate) -2- 4:23 PM Mar 27, 2013  PR
    Biogen Idec's TECFIDERA(TM) (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis 4:23 PM Mar 27, 2013  PR
    FDA Approves Biogen Treatment for MS 4:21 PM Mar 27, 2013 Dow Jones Global News Select
    Biogen Idec's TECFIDERA(TM) (Dimethyl Fumarate) -2- 4:10 PM Mar 27, 2013  PR
    Biogen Idec's TECFIDERA(TM) (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis 4:10 PM Mar 27, 2013  PR
    • Print Snapshot
    • Stock Compare
    • Receive Stock Alerts
    • Receive News Alerts
    • Glossary
    • RSS
    • Price Check Calculator
    • Annual Reports
    tools

    Stock Screener

    Portfolio Tracker

    See More Tools